english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

The covid-19 messenger RNA vaccine from Moderna: as with the tozinameran vaccine (Comirnaty°, Pfizer/BioNTech), limited data and unanswered questions

 NEWS UPDATE  As of early January 2021, the covid-19 vaccine mRNA-1273 Sars-CoV-2, from the pharmaceutical company Moderna, is expected to be approved for use in the European Union. In France, this vaccine is to be offered first to elderly residents of nursing homes and similar facilities, and to certain health professionals. What are the main evaluation data obtained with this vaccine in these populations? 
06 January 2021

SSRI antidepressants and pregnancy: long-term neuropsychiatric disorders in exposed children?

FEATURED REVIEW Data available in 2017 suggested that in utero exposure to SSRI antidepressants increases the risk of autism. Do we have a clearer idea in 2020 of the long-term neuropsychiatric harms to the unborn child posed by the use of SSRI antidepressants during pregnancy?
Full review (3 pages) available for download by subscribers.
1 January 2021

In the January issue of Prescrire International: Dasatinib (Sprycel° and other brands) in children with acute lymphoblastic leukaemia

FREE DOWNLOAD Dasatinib has been granted marketing authorisation in the European Union as first-line therapy added to chemotherapy for children with Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Full text available for free download.
1 January 2021

A two-step approach

EDITORIAL In the midst of the covid-19 crisis, Prescrire is fulfilling its mission via a two-step approach. Rapidly sharing key information, distinguishing fact from hypothesis and opinion. Then helping healthcare professionals to make rational choices, based on documented evidence rather than wishful thinking. Taking care not to confuse urgent action with undue haste.
1 January 2021

Treatment-resistant depression: avoid esketamine (Spravato°)

Esketamine nasal spray (Spravato°) has been authorised for use in so-called "treatment-resistant" depression. Its efficacy is uncertain, and its harm-benefit balance is unfavourable due to serious adverse effects including neuropsychiatric and cardiac disorders.
1 January 2021

Adverse effects of cancer drugs: often downplayed in articles reporting the results of clinical trials

The adverse effects that occurred during clinical trials are often omitted in articles, or described using subjective terms.
1 January 2021

The covid-19 messenger RNA vaccine tozinameran (Comirnaty°, from Pfizer and BioNTech) in elderly patients: limited data, many uncertainties

 NEWS UPDATE  The vaccination campaign against the covid-19 epidemic is launching in late December 2020. The first populations to whom the French authorities have chosen to offer this covid-19 messenger RNA vaccine (marketed by the pharmaceutical companies Pfizer and BioNTech) are nursing home residents and certain health professionals who work in these facilities. What are the main data from the clinical evaluation of this vaccine in this population?
23 December 2020

Covid-19 and vitamin D: too uncertain

 NEWS UPDATE  Interest has been expressed in using vitamin D in the prevention of Sars-CoV-2 infection or the treatment of covid-19. What evaluation data available as of late 2020 support this hypothesis?
15 December 2020

Fexinidazole (Fexinidazole Winthrop°) and sleeping sickness caused by Trypanosoma brucei gambiense

FEATURED REVIEW Human African trypanosomiasis (or sleeping sickness) is endemic in many countries in sub-Saharan Africa. Is fexinidazole more effective than the standard treatments for sleeping sickness due to T. brucei gambiense? Does it have fewer adverse effects? Is it easier to use?
Full review (5 pages) available for download by subscribers.
1 December 2020

An exemplary initiative

EDITORIALA successful collaboration between the Drugs for Neglected Diseases initiative (DNDi) and several other entities has shown that it is possible to develop drugs that satisfy a genuine need, with the sole aim of providing a therapeutic advance, without the promise of exclusive market access or huge profits.
1 December 2020

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90